Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology


如何引用文章

全文:

详细

:Microtubule-Associated Protein Tau (also known as tau) has been shown to accumulate into paired helical filaments and neurofibrillary tangles, which are known hallmarks of Alzheimer’s disease (AD) pathology. Decades of research have shown that tau protein undergoes extensive post-translational modifications (PTMs), which can alter the protein's structure, function, and dynamics and impact the various properties such as solubility, aggregation, localization, and homeostasis. There is a vast amount of information describing the impact and role of different PTMs in AD pathology and neuroprotection. However, the complex interplay between these PTMs remains elusive. Therefore, in this review, we aim to comprehend the key post-translational modifications occurring in tau and summarize potential connections to clarify their impact on the physiology and pathophysiology of tau. Further, we describe how different computational modeling methods have helped in understanding the impact of PTMs on the structure and functions of the tau protein. Finally, we highlight the tau PTM-related therapeutics strategies that are explored for the development of AD therapy.

作者简介

Subha Kalyaanamoorthy

Department of Chemistry, University of Waterloo

编辑信件的主要联系方式.
Email: info@benthamscience.net

Stanley Opare

Department of Chemistry, University of Waterloo

Email: info@benthamscience.net

Xiaoxiao Xu

Chemistry, University of Waterloo

Email: info@benthamscience.net

Aravindhan Ganesan

Department of Chemistry, University of Waterloo

Email: info@benthamscience.net

Praveen Rao

Department of Chemistry, University of Waterloo

Email: info@benthamscience.net

参考

  1. Jha, A.; Mukhopadhaya, K. Memory, cognitive impairment and dementia. In: Alzheimer’s Disease: Diagnosis and Treatment Guide; Springer International Publishing: Cham, 2021; pp. 1-20. doi: 10.1007/978-3-030-56739-2_1
  2. Matthews, K.A.; Xu, W.; Gaglioti, A.H.; Holt, J.B.; Croft, J.B.; Mack, D.; McGuire, L.C. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement., 2019, 15(1), 17-24. doi: 10.1016/j.jalz.2018.06.3063 PMID: 30243772
  3. Alzheimer’s disease and related dementias. 2020. Available from: https://www.cdc.gov/aging
  4. Gauthier, S. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. In: World Alzheimer Reports; Benoist Chloe, W.W., Ed.; Alzheimer’s Disease International, 2022; p. 413.
  5. Meyers, E.A.; Sexton, C.; Snyder, H.M.; Carrillo, M.C. Impact of Alzheimer’s association support and engagement in the AD/ADRD research community through the COVID-19 pandemic and beyond. Alzheimers Dement., 2023, 19(7), 3222-3225. doi: 10.1002/alz.13015 PMID: 36872646
  6. Tay, L.X.; Ong, S.C.; Tay, L.J.; Ng, T.; Parumasivam, T. Economic burden of alzheimer’s disease: A systematic review. Value Health Reg. Issues, 2024, 40, 1-12. doi: 10.1016/j.vhri.2023.09.008 PMID: 37972428
  7. Global action plan on the public health response to dementia 2017-2025. Ed.; World Health Organization. 2017
  8. Achúcarro, N. Elongated and stäbechenzellen cells: Neuroglic cells and granulo-adipose cells at the Ammon horn of the rabbit; Nicolás Moya, 1909.
  9. Achúcarro, N. Notes on the structure and functions of neuroglia and in particular of neuroglia of the human cerebral cortex; Children of Nicolás Moya, 1914.
  10. Kim, S.R.; Lee, J.M. Prothrombin kringle-2, a mediator of microglial activation: new insight in Alzheimer’s disease pathogenesis. Neural Regen. Res., 2022, 17(12), 2675-2676. doi: 10.4103/1673-5374.335813 PMID: 35662205
  11. Stelzmann, R.A.; Schnitzlein, H.N.; Murtagh, F.R.; Murtagh, F.R. An english translation of alzheimer’s 1907 paper, "über eine eigenartige erkankung der hirnrinde". Clin. Anat., 1995, 8(6), 429-431. doi: 10.1002/ca.980080612 PMID: 8713166
  12. Swerdlow, R.H.; Anderson, H.; Burns, J.M. Alzheimer’s disease. In: Encyclopedia of Clinical Neuropsychology; Kreutzer, J.S.; DeLuca, J.; Caplan, B., Eds.; Springer New York: New York, NY, 2011; pp. 105-110. doi: 10.1007/978-0-387-79948-3_290
  13. Mattson, M.P. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer’s disease. J. Neurovirol., 2002, 8(6), 539-550. doi: 10.1080/13550280290100978 PMID: 12476348
  14. Cabezas, I.L.; Batista, A.H.; Rol, G.P. The role of glial cells in Alzheimer disease: Potential therapeutic implications. Neurologia, 2014, 29(5), 305-309. doi: 10.1016/j.nrl.2012.10.006 PMID: 23246214
  15. Sahara, N.; Maeda, S.; Takashima, A. Tau oligomerization: A role for tau aggregation intermediates linked to neurodegeneration. Curr. Alzheimer Res., 2008, 5(6), 591-598. doi: 10.2174/156720508786898442 PMID: 19075586
  16. Hosokawa, M.; Masuda-Suzukake, M.; Shitara, H.; Shimozawa, A.; Suzuki, G.; Kondo, H.; Nonaka, T.; Campbell, W.; Arai, T.; Hasegawa, M. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms. Brain, 2022, 145(1), 349-361. doi: 10.1093/brain/awab289 PMID: 34515757
  17. Tsujikawa, K.; Hamanaka, K.; Riku, Y.; Hattori, Y.; Hara, N.; Iguchi, Y.; Ishigaki, S.; Hashizume, A.; Miyatake, S.; Mitsuhashi, S.; Miyazaki, Y.; Kataoka, M.; Jiayi, L.; Yasui, K.; Kuru, S.; Koike, H.; Kobayashi, K.; Sahara, N.; Ozaki, N.; Yoshida, M.; Kakita, A.; Saito, Y.; Iwasaki, Y.; Miyashita, A.; Iwatsubo, T.; Ikeuchi, T.; Miyata, T.; Sobue, G.; Matsumoto, N.; Sahashi, K.; Katsuno, M. Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Sci. Adv., 2022, 8(21), eabm5029. doi: 10.1126/sciadv.abm5029 PMID: 35613261
  18. Lukiw, W.J. Recent advances in our molecular and mechanistic understanding of misfolded cellular proteins in alzheimer’s disease (AD) and prion disease (PrD). Biomolecules, 2022, 12(2), 166. doi: 10.3390/biom12020166 PMID: 35204666
  19. Petrozziello, T.; Bordt, E.A.; Mills, A.N.; Kim, S.E.; Sapp, E.; Devlin, B.A.; Obeng-Marnu, A.A.; Farhan, S.M.K.; Amaral, A.C.; Dujardin, S.; Dooley, P.M.; Henstridge, C.; Oakley, D.H.; Neueder, A.; Hyman, B.T.; Spires-Jones, T.L.; Bilbo, S.D.; Vakili, K.; Cudkowicz, M.E.; Berry, J.D.; DiFiglia, M.; Silva, M.C.; Haggarty, S.J.; Sadri-Vakili, G. Targeting tau mitigates mitochondrial fragmentation and oxidative stress in amyotrophic lateral sclerosis. Mol. Neurobiol., 2022, 59(1), 683-702. doi: 10.1007/s12035-021-02557-w PMID: 34757590
  20. Liang, S.Y.; Wang, Z.T.; Tan, L.; Yu, J.T. Tau toxicity in neurodegeneration. Mol. Neurobiol., 2022, 59(6), 3617-3634. doi: 10.1007/s12035-022-02809-3 PMID: 35359226
  21. Maeda, S.; Sahara, N.; Saito, Y.; Murayama, M.; Yoshiike, Y.; Kim, H.; Miyasaka, T.; Murayama, S.; Ikai, A.; Takashima, A. Granular tau oligomers as intermediates of tau filaments. Biochemistry, 2007, 46(12), 3856-3861. doi: 10.1021/bi061359o PMID: 17338548
  22. Gerson, J.E.; Sengupta, U.; Lasagna-Reeves, C.A.; Guerrero- Muñoz, M.J.; Troncoso, J.; Kayed, R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun., 2014, 2(1), 73. doi: 10.1186/2051-5960-2-73 PMID: 24927818
  23. Shafiei, S.S.; Guerrero-Muñoz, M.J.; Castillo-Carranza, D.L. Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage. Front. Aging Neurosci., 2017, 9, 83. doi: 10.3389/fnagi.2017.00083 PMID: 28420982
  24. Peeraer, E.; Bottelbergs, A.; van Kolen, K.; Stancu, I.C.; Vasconcelos, B.; Mahieu, M.; Duytschaever, H.; Ver Donck, L.; Torremans, A.; Sluydts, E.; Van Acker, N.; Kemp, J.A.; Mercken, M.; Brunden, K.R.; Trojanowski, J.Q.; Dewachter, I.; Lee, V.M.Y.; Moechars, D. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis., 2015, 73, 83-95. doi: 10.1016/j.nbd.2014.08.032 PMID: 25220759
  25. Alquezar, C.; Arya, S.; Kao, A.W. Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation. Front. Neurol., 2021, 11, 595532. doi: 10.3389/fneur.2020.595532 PMID: 33488497
  26. Marcelli, S.; Corbo, M.; Iannuzzi, F.; Negri, L.; Blandini, F.; Nistico, R.; Feligioni, M. The involvement of post-translational modifications in alzheimer’s disease. Curr. Alzheimer Res., 2018, 15(4), 313-335. doi: 10.2174/1567205014666170505095109 PMID: 28474569
  27. Selkoe, D.J. The therapeutics of Alzheimer’s disease: Where we stand and where we are heading. Ann. Neurol., 2013, 74(3), 328-336. doi: 10.1002/ana.24001 PMID: 25813842
  28. Ashraf, G.; Greig, N.; Khan, T.; Hassan, I.; Tabrez, S.; Shakil, S.; Sheikh, I.; Zaidi, S.; Akram, M.; Jabir, N.; Firoz, C.; Naeem, A.; Alhazza, I.; Damanhouri, G.; Kamal, M. Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets, 2014, 13(7), 1280-1293. doi: 10.2174/1871527313666140917095514 PMID: 25230234
  29. Braak, H.; Braak, E. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiol. Aging, 1995, 16(3), 271-278. doi: 10.1016/0197-4580(95)00021-6 PMID: 7566337
  30. Iqbal, K.; Novak, M. From tangles to tau protein. Bratisl. Lek Listy, 2006, 107(9-10), 341-342. PMID: 17262984
  31. Fuentes, P.; Catalan, J. A clinical perspective: Anti tau’s treatment in Alzheimer’s disease. Curr. Alzheimer Res., 2011, 8(6), 686-688. doi: 10.2174/156720511796717221 PMID: 21605037
  32. Ceyzériat, K.; Zilli, T.; Millet, P.; Frisoni, G.B.; Garibotto, V.; Tournier, B.B. Learning from the past: A review of clinical trials targeting amyloid, tau and neuroinflammation in alzheimer’s disease. Curr. Alzheimer Res., 2020, 17(2), 112-125. doi: 10.2174/1567205017666200304085513 PMID: 32129164
  33. Cook, C.; Stankowski, J.N.; Carlomagno, Y.; Stetler, C.; Petrucelli, L. Acetylation: A new key to unlock tau’s role in neurodegeneration. Alzheimers Res. Ther., 2014, 6(3), 29. doi: 10.1186/alzrt259 PMID: 25031639
  34. Wegmann, S.; Biernat, J.; Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimer’s disease. Curr. Opin. Neurobiol., 2021, 69, 131-138. doi: 10.1016/j.conb.2021.03.003 PMID: 33892381
  35. Park, S.; Lee, J.H.; Jeon, J.H.; Lee, M.J. Degradation or aggregation: The ramifications of post-translational modifications on tau. BMB Rep., 2018, 51(6), 265-273. doi: 10.5483/BMBRep.2018.51.6.077 PMID: 29661268
  36. Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol., 2019, 15(6), 346-366. doi: 10.1038/s41581-019-0129-4 PMID: 30858582
  37. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Yoshida, H.; Watanabe, A.; Titani, K.; Ihara, Y. Hyperphosphorylation of Tau in PHF. Neurobiol. Aging, 1995, 16(3), 365-371. doi: 10.1016/0197-4580(95)00027-C PMID: 7566346
  38. Haukedal, H.; Freude, K.K. Implications of glycosylation in alzheimer’s disease. Front. Neurosci., 2021, 14, 625348. doi: 10.3389/fnins.2020.625348 PMID: 33519371
  39. Yang, X.J.; Seto, E. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Mol. Cell, 2008, 31(4), 449-461. doi: 10.1016/j.molcel.2008.07.002 PMID: 18722172
  40. Funk, K.E.; Thomas, S.N.; Schafer, K.N.; Cooper, G.L.; Liao, Z.; Clark, D.J.; Yang, A.J.; Kuret, J. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem. J., 2014, 462(1), 77-88. doi: 10.1042/BJ20140372 PMID: 24869773
  41. Gong, C.X.; Liu, F.; Iqbal, K. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration. Alzheimers Dement., 2016, 12(10), 1078-1089. doi: 10.1016/j.jalz.2016.02.011 PMID: 27126545
  42. Mondragón-Rodríguez, S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: Implications for Alzheimer’s disease. Oxid Med Cell Longev., 2013, 2013, 940603. doi: 10.1155/2013/940603
  43. Gong, C.X.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K. Post-translational modifications of tau protein in Alzheimer’s disease. J. Neural Transm., 2005, 112(6), 813-838. doi: 10.1007/s00702-004-0221-0 PMID: 15517432
  44. Liu, F.; Zaidi, T.; Iqbal, K.; Grundke-Iqbal, I.; Merkle, R.K.; Gong, C.X. Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS Lett., 2002, 512(1-3), 101-106. doi: 10.1016/S0014-5793(02)02228-7 PMID: 11852060
  45. Ye, H.; Han, Y.; Li, P.; Su, Z.; Huang, Y. The role of post-translational modifications on the structure and function of tau protein. J. Mol. Neurosci., 2022, 72(8), 1557-1571. doi: 10.1007/s12031-022-02002-0 PMID: 35325356
  46. Mandel, N.; Agarwal, N. Role of SUMOylation in neurodegenerative diseases. Cells, 2022, 11(21), 3395. doi: 10.3390/cells11213395 PMID: 36359791
  47. Sarge, K.D.; Park-Sarge, O.K. SUMOylation and human disease pathogenesis. Trends Biochem. Sci., 2009, 34(4), 200-205. doi: 10.1016/j.tibs.2009.01.004 PMID: 19282183
  48. Stoothoff, W.H.; Johnson, G.V.W. Tau phosphorylation: Physiological and pathological consequences. Biochim. Biophys. Acta Mol. Basis Dis., 2005, 1739(2-3), 280-297. doi: 10.1016/j.bbadis.2004.06.017 PMID: 15615646
  49. Morris, M.; Knudsen, G.M.; Maeda, S.; Trinidad, J.C.; Ioanoviciu, A.; Burlingame, A.L.; Mucke, L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci., 2015, 18(8), 1183-1189. doi: 10.1038/nn.4067 PMID: 26192747
  50. Guillozet-Bongaarts, A.L.; Garcia-Sierra, F.; Reynolds, M.R.; Horowitz, P.M.; Fu, Y.; Wang, T.; Cahill, M.E.; Bigio, E.H.; Berry, R.W.; Binder, L.I. Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease. Neurobiol. Aging, 2005, 26(7), 1015-1022. doi: 10.1016/j.neurobiolaging.2004.09.019 PMID: 15748781
  51. Li, L.; Jiang, Y.; Wang, J.Z.; Liu, R.; Wang, X. Tau ubiquitination in alzheimer’s disease. Front. Neurol., 2022, 12, 786353. doi: 10.3389/fneur.2021.786353 PMID: 35211074
  52. Oliveira, J.; Costa, M.; de Almeida, M.S.C.; da Cruz e Silva, O.A.B.; Henriques, A.G. Protein phosphorylation is a key mechanism in Alzheimer’s disease. J. Alzheimers Dis., 2017, 58(4), 953-978. doi: 10.3233/JAD-170176 PMID: 28527217
  53. Tolnay, M.; Sergeant, N.; Ghestem, A.; Chalbot, S.; de Vos, R.A.; Jansen Steur, E.N.; Probst, A.; Delacourte, A. Argyrophilic grain disease and Alzheimer’s disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol., 2002, 104(4), 425-434. doi: 10.1007/s00401-002-0591-z PMID: 12200631
  54. Drepper, F.; Biernat, J.; Kaniyappan, S.; Meyer, H.E.; Mandelkow, E.M.; Warscheid, B.; Mandelkow, E. A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications. J. Biol. Chem., 2020, 295(52), 18213-18225. doi: 10.1074/jbc.RA120.015882 PMID: 33106314
  55. Kimura, T.; Sharma, G.; Ishiguro, K.; Hisanaga, S. Phospho-tau bar code: Analysis of phosphoisotypes of tau and its application to tauopathy. Front. Neurosci., 2018, 12, 44. doi: 10.3389/fnins.2018.00044 PMID: 29467609
  56. Hanger, D.P.; Anderton, B.H.; Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med., 2009, 15(3), 112-119. doi: 10.1016/j.molmed.2009.01.003 PMID: 19246243
  57. Buée, L.; Bussière, T.; Buée-Scherrer, V.; Delacourte, A.; Hof, P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev., 2000, 33(1), 95-130. doi: 10.1016/S0165-0173(00)00019-9 PMID: 10967355
  58. Haj-Yahya, M. Site-specific hyperphosphorylation of tau inhibits its fibrillization in vitro, blocks its seeding capacity in cells, and disrupts its microtubule binding; Implications for the native state stabilization of tau. bioRxiv, 2019, 772046. doi: 10.1101/772046
  59. Zhou, X.W.; Li, X.; Bjorkdahl, C.; Sjogren, M.J.; Alafuzoff, I.; Soininen, H.; Grundke-Iqbal, I.; Iqbal, K.; Winblad, B.; Pei, J.J. Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer’s brains. Neurobiol. Dis., 2006, 22(3), 657-668. doi: 10.1016/j.nbd.2006.01.006 PMID: 16513361
  60. Šimić, G.; Babić Leko, M.; Wray, S.; Harrington, C.; Delalle, I.; Jovanov-Milošević, N.; Bažadona, D.; Buée, L.; de Silva, R.; Di Giovanni, G.; Wischik, C.; Hof, P. Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules, 2016, 6(1), 6. doi: 10.3390/biom6010006 PMID: 26751493
  61. Su, J.H.; Cummings, B.J.; Cotman, C.W. Early phosphorylation of tau in Alzheimerʼs disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport, 1994, 5(17), 2358-2362. doi: 10.1097/00001756-199411000-00037 PMID: 7533559
  62. Iqbal, K.; Grundke-Iqbal, I. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer’s disease. Mol. Neurobiol., 1991, 5(2-4), 399-410. doi: 10.1007/BF02935561 PMID: 1726645
  63. Guillozet-Bongaarts, A.L.; Cahill, M.E.; Cryns, V.L.; Reynolds, M.R.; Berry, R.W.; Binder, L.I. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: In vitro evidence and implications for tangle formation in vivo. J. Neurochem., 2006, 97(4), 1005-1014. doi: 10.1111/j.1471-4159.2006.03784.x PMID: 16606369
  64. Dickey, C.A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R.M.; Dunmore, J.; Ash, P.; Shoraka, S.; Zlatkovic, J.; Eckman, C.B.; Patterson, C.; Dickson, D.W.; Nahman, N.S., Jr; Hutton, M.; Burrows, F.; Petrucelli, L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest., 2007, 117(3), 648-658. doi: 10.1172/JCI29715 PMID: 17304350
  65. Hoover, B.R.; Reed, M.N.; Su, J.; Penrod, R.D.; Kotilinek, L.A.; Grant, M.K.; Pitstick, R.; Carlson, G.A.; Lanier, L.M.; Yuan, L.L.; Ashe, K.H.; Liao, D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 2010, 68(6), 1067-1081. doi: 10.1016/j.neuron.2010.11.030 PMID: 21172610
  66. Lu, P.J.; Wulf, G.; Zhou, X.Z.; Davies, P.; Lu, K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature, 1999, 399(6738), 784-788. doi: 10.1038/21650 PMID: 10391244
  67. Kondo, A.; Shahpasand, K.; Mannix, R.; Qiu, J.; Moncaster, J.; Chen, C.H.; Yao, Y.; Lin, Y.M.; Driver, J.A.; Sun, Y.; Wei, S.; Luo, M.L.; Albayram, O.; Huang, P.; Rotenberg, A.; Ryo, A.; Goldstein, L.E.; Pascual-Leone, A.; McKee, A.C.; Meehan, W.; Zhou, X.Z.; Lu, K.P. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature, 2015, 523(7561), 431-436. doi: 10.1038/nature14658 PMID: 26176913
  68. Lee, T.H.; Chen, C.H.; Suizu, F.; Huang, P.; Schiene-Fischer, C.; Daum, S.; Zhang, Y.J.; Goate, A.; Chen, R.H.; Zhou, X.Z.; Lu, K.P. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol. Cell, 2011, 42(2), 147-159. doi: 10.1016/j.molcel.2011.03.005 PMID: 21497122
  69. Balastik, M.; Lim, J.; Pastorino, L.; Lu, K.P. Pin1 in Alzheimer’s disease: Multiple substrates, one regulatory mechanism? Biochim. Biophys. Acta Mol. Basis Dis., 2007, 1772(4), 422-429. doi: 10.1016/j.bbadis.2007.01.006 PMID: 17317113
  70. Buerger, K.; Ewers, M.; Pirttilä, T.; Zinkowski, R.; Alafuzoff, I.; Teipel, S.J.; DeBernardis, J.; Kerkman, D.; McCulloch, C.; Soininen, H.; Hampel, H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain, 2006, 129(11), 3035-3041. doi: 10.1093/brain/awl269 PMID: 17012293
  71. Gong, C.X.; Singh, T.J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem., 1993, 61(3), 921-927. doi: 10.1111/j.1471-4159.1993.tb03603.x PMID: 8395566
  72. Chen, S.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J. Biol. Chem., 2008, 283(16), 10513-10521. doi: 10.1074/jbc.M709852200 PMID: 18245083
  73. Hart, G.W.; Slawson, C.; Ramirez-Correa, G.; Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem., 2011, 80(1), 825-858. doi: 10.1146/annurev-biochem-060608-102511 PMID: 21391816
  74. Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G.W.; Gong, C.X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10804-10809. doi: 10.1073/pnas.0400348101 PMID: 15249677
  75. O’Donnell, N.; Zachara, N.E.; Hart, G.W.; Marth, J.D. Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol. Cell. Biol., 2004, 24(4), 1680-1690. doi: 10.1128/MCB.24.4.1680-1690.2004 PMID: 14749383
  76. Soeda, Y.; Takashima, A. New insights into drug discovery targeting tau protein. Front. Mol. Neurosci., 2020, 13, 590896. doi: 10.3389/fnmol.2020.590896 PMID: 33343298
  77. Carlomagno, Y.; Chung, D.C.; Yue, M.; Castanedes-Casey, M.; Madden, B.J.; Dunmore, J.; Tong, J.; DeTure, M.; Dickson, D.W.; Petrucelli, L.; Cook, C. An acetylation–phosphorylation switch that regulates tau aggregation propensity and function. J. Biol. Chem., 2017, 292(37), 15277-15286. doi: 10.1074/jbc.M117.794602 PMID: 28760828
  78. Xia, Y.; Bell, B.M.; Giasson, B.I. Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau–microtubule interactions and inhibits aggregation. Sci. Rep., 2021, 11(1), 17069. doi: 10.1038/s41598-021-96627-7 PMID: 34426645
  79. Julien, C.; Tremblay, C.; Émond, V.; Lebbadi, M.; Salem, N., Jr; Bennett, D.A.; Calon, F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2009, 68(1), 48-58. doi: 10.1097/NEN.0b013e3181922348 PMID: 19104446
  80. Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; Meyers, D.; Cole, P.A.; Ott, M.; Gan, L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 2010, 67(6), 953-966. doi: 10.1016/j.neuron.2010.08.044 PMID: 20869593
  81. Gorsky, M.K.; Burnouf, S.; Dols, J.; Mandelkow, E.; Partridge, L. Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci. Rep., 2016, 6(1), 22685. doi: 10.1038/srep22685 PMID: 26940749
  82. Cohen, T.J.; Guo, J.L.; Hurtado, D.E.; Kwong, L.K.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M.Y. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun., 2011, 2(1), 252. doi: 10.1038/ncomms1255 PMID: 21427723
  83. Min, S.W.; Chen, X.; Tracy, T.E.; Li, Y.; Zhou, Y.; Wang, C.; Shirakawa, K.; Minami, S.S.; Defensor, E.; Mok, S.A.; Sohn, P.D.; Schilling, B.; Cong, X.; Ellerby, L.; Gibson, B.W.; Johnson, J.; Krogan, N.; Shamloo, M.; Gestwicki, J.; Masliah, E.; Verdin, E.; Gan, L. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med., 2015, 21(10), 1154-1162. doi: 10.1038/nm.3951 PMID: 26390242
  84. Boulton, T.G.; Yancopoulos, G.D.; Gregory, J.S.; Slaughter, C.; Moomaw, C.; Hsu, J.; Cobb, M.H. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science, 1990, 249(4964), 64-67. doi: 10.1126/science.2164259 PMID: 2164259
  85. Cohen, T.J.; Friedmann, D.; Hwang, A.W.; Marmorstein, R.; Lee, V.M.Y. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat. Struct. Mol. Biol., 2013, 20(6), 756-762. doi: 10.1038/nsmb.2555 PMID: 23624859
  86. Cohen, T.J.; Constance, B.H.; Hwang, A.W.; James, M.; Yuan, C.X. Intrinsic tau acetylation is coupled to auto-proteolytic tau fragmentation. PLoS One, 2016, 11(7), e0158470. doi: 10.1371/journal.pone.0158470 PMID: 27383765
  87. Luo, Y.; Ma, B.; Nussinov, R.; Wei, G. Structural insight into tau protein’s paradox of intrinsically disordered behavior, self-acetylation activity, and aggregation. J. Phys. Chem. Lett., 2014, 5(17), 3026-3031. doi: 10.1021/jz501457f PMID: 25206938
  88. Sohn, P.D.; Tracy, T.E.; Son, H.I.; Zhou, Y.; Leite, R.E.P.; Miller, B.L.; Seeley, W.W.; Grinberg, L.T.; Gan, L. Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol. Neurodegener., 2016, 11(1), 47. doi: 10.1186/s13024-016-0109-0 PMID: 27356871
  89. Cook, C.; Carlomagno, Y.; Gendron, T.F.; Dunmore, J.; Scheffel, K.; Stetler, C.; Davis, M.; Dickson, D.; Jarpe, M.; DeTure, M.; Petrucelli, L. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet., 2014, 23(1), 104-116. doi: 10.1093/hmg/ddt402 PMID: 23962722
  90. Yao, Z.; Gao, M.; Huang, Y. Acetylation of lysine residues within the MT-binding repeats specifically modulates the structure ensemble of Tau. FASEB J., 2018, 32(S1), lb34-lb34. doi: 10.1096/fasebj.2018.32.1_supplement.lb34
  91. Thomas, S.N.; Funk, K.E.; Wan, Y.; Liao, Z.; Davies, P.; Kuret, J.; Yang, A.J. Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: A mass spectrometry approach. Acta Neuropathol., 2012, 123(1), 105-117. doi: 10.1007/s00401-011-0893-0 PMID: 22033876
  92. Balmik, A.A.; Chinnathambi, S. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer’s disease. Cell Commun. Signal., 2021, 19(1), 51. doi: 10.1186/s12964-021-00732-z PMID: 33962636
  93. Kontaxi, C.; Piccardo, P.; Gill, A.C. Lysine-directed post-translational modifications of tau protein in Alzheimer’s disease and related tauopathies. Front. Mol. Biosci., 2017, 4, 56. doi: 10.3389/fmolb.2017.00056 PMID: 28848737
  94. Shams, H.; Matsunaga, A.; Ma, Q.; Mofrad, M.R.K.; Didonna, A. Methylation at a conserved lysine residue modulates tau assembly and cellular functions. Mol. Cell. Neurosci., 2022, 120, 103707. doi: 10.1016/j.mcn.2022.103707 PMID: 35231567
  95. Bichmann, M.; Prat Oriol, N.; Ercan-Herbst, E.; Schöndorf, D.C.; Gomez Ramos, B.; Schwärzler, V.; Neu, M.; Schlüter, A.; Wang, X.; Jin, L.; Hu, C.; Tian, Y.; Ried, J.S.; Haberkant, P.; Gasparini, L.; Ehrnhoefer, D.E. SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease. Mol. Neurodegener., 2021, 16(1), 46. doi: 10.1186/s13024-021-00468-x PMID: 34215303
  96. Wang, P.; Joberty, G.; Buist, A.; Vanoosthuyse, A.; Stancu, I.C.; Vasconcelos, B.; Pierrot, N.; Faelth-Savitski, M.; Kienlen-Campard, P.; Octave, J.N.; Bantscheff, M.; Drewes, G.; Moechars, D.; Dewachter, I. Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. Acta Neuropathol., 2017, 133(5), 731-749. doi: 10.1007/s00401-016-1663-9 PMID: 28083634
  97. Xu, Z.; Kohli, E.; Devlin, K.I.; Bold, M.; Nix, J.C.; Misra, S. Interactions between the quality control ubiquitin ligase CHIP and ubiquitin conjugating enzymes. BMC Struct. Biol., 2008, 8(1), 26. doi: 10.1186/1472-6807-8-26 PMID: 18485199
  98. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W.H.; Browne, S.E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T.M.; Wolozin, B.; Hardy, J.; Hutton, M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet., 2004, 13(7), 703-714. doi: 10.1093/hmg/ddh083 PMID: 14962978
  99. Flach, K.; Ramminger, E.; Hilbrich, I.; Arsalan-Werner, A.; Albrecht, F.; Herrmann, L.; Goedert, M.; Arendt, T.; Holzer, M. Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochim. Biophys. Acta Mol. Basis Dis., 2014, 1842(9), 1527-1538. doi: 10.1016/j.bbadis.2014.05.029 PMID: 24905733
  100. Babu, J.R.; Geetha, T.; Wooten, M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem., 2005, 94(1), 192-203. doi: 10.1111/j.1471-4159.2005.03181.x PMID: 15953362
  101. Cripps, D.; Thomas, S.N.; Jeng, Y.; Yang, F.; Davies, P.; Yang, A.J. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem., 2006, 281(16), 10825-10838. doi: 10.1074/jbc.M512786200 PMID: 16443603
  102. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Titani, K.; Ihara, Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron, 1993, 10(6), 1151-1160. doi: 10.1016/0896-6273(93)90063-W PMID: 8391280
  103. Dolan, P.J.; Johnson, G.V.W. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J. Biol. Chem., 2010, 285(29), 21978-21987. doi: 10.1074/jbc.M110.110940 PMID: 20466727
  104. Puangmalai, N.; Sengupta, U.; Bhatt, N.; Gaikwad, S.; Montalbano, M.; Bhuyan, A.; Garcia, S.; McAllen, S.; Sonawane, M.; Jerez, C.; Zhao, Y.; Kayed, R. Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease. J. Biol. Chem., 2022, 298(4), 101766. doi: 10.1016/j.jbc.2022.101766 PMID: 35202653
  105. Perry, G.; Friedman, R.; Shaw, G.; Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA, 1987, 84(9), 3033-3036. doi: 10.1073/pnas.84.9.3033 PMID: 3033674
  106. García-Sierra, F.; Jarero-Basulto, J.J.; Kristofikova, Z.; Majer, E.; Binder, L.I.; Ripova, D. Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimer’s disease. Brain Pathol., 2012, 22(2), 240-250. doi: 10.1111/j.1750-3639.2011.00525.x PMID: 21919991
  107. Chakrabarty, R.; Yousuf, S.; Singh, M.P. Contributive role of hyperglycemia and hypoglycemia towards the development of alzheimer’s disease. Mol. Neurobiol., 2022, 59(7), 4274-4291. doi: 10.1007/s12035-022-02846-y PMID: 35503159
  108. Weeraratna, A.T.; Kalehua, A.; DeLeon, I.; Bertak, D.; Maher, G.; Wade, M.S.; Lustig, A.; Becker, K.G.; Wood, W., III; Walker, D.G.; Beach, T.G.; Taub, D.D. Alterations in immunological and neurological gene expression patterns in Alzheimer’s disease tissues. Exp. Cell Res., 2007, 313(3), 450-461. doi: 10.1016/j.yexcr.2006.10.028 PMID: 17188679
  109. Chenfei, Z.; Haizhen, Y.; Jie, X.; Na, Z.; Bo, X. Effects of aerobic exercise on hippocampal SUMOylation in APP/PS1 transgenic mice. Neurosci. Lett., 2022, 767, 136303. doi: 10.1016/j.neulet.2021.136303 PMID: 34695453
  110. Dorval, V.; Fraser, P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein. J. Biol. Chem., 2006, 281(15), 9919-9924. doi: 10.1074/jbc.M510127200 PMID: 16464864
  111. Luo, H.B.; Xia, Y.Y.; Shu, X.J.; Liu, Z.C.; Feng, Y.; Liu, X.H.; Yu, G.; Yin, G.; Xiong, Y.S.; Zeng, K.; Jiang, J.; Ye, K.; Wang, X.C.; Wang, J.Z. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl. Acad. Sci. USA, 2014, 111(46), 16586-16591. doi: 10.1073/pnas.1417548111 PMID: 25378699
  112. Nagaraju, P.G.; Priyadarshini, P. Tau-aggregation inhibition: Promising role of nanoencapsulated dietary molecules in the management of Alzheimer’s disease. Crit. Rev. Food Sci. Nutr., 2023, 63(32), 11153-11168. PMID: 35748395
  113. Qin, M.; Li, H.; Bao, J.; Xia, Y.; Ke, D.; Wang, Q.; Liu, R.; Wang, J.Z.; Zhang, B.; Shu, X.; Wang, X. SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments. Acta Neuropathol. Commun., 2019, 7(1), 21. doi: 10.1186/s40478-019-0663-0 PMID: 30767764
  114. Orsini, F. SUMO2 protects against tau-induced synaptic and cognitive dysfunction. bioRxiv, 2022. doi: 10.1101/2022.11.11.516192
  115. Kovacech, B.; Novak, M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer’s disease. Curr. Alzheimer Res., 2010, 7(8), 708-716. doi: 10.2174/156720510793611556 PMID: 20678071
  116. Abraha, A.; Ghoshal, N.; Gamblin, T.C.; Cryns, V.; Berry, R.W.; Kuret, J.; Binder, L.I. C-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease. J. Cell Sci., 2000, 113(21), 3737-3745. doi: 10.1242/jcs.113.21.3737 PMID: 11034902
  117. Novak, M.; Kabat, J.; Wischik, C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J., 1993, 12(1), 365-370. doi: 10.1002/j.1460-2075.1993.tb05665.x PMID: 7679073
  118. Loon, A.; Zamudio, F.; Sanneh, A.; Brown, B.; Smeltzer, S.; Brownlow, M.L.; Quadri, Z.; Peters, M.; Weeber, E.; Nash, K.; Lee, D.C.; Gordon, M.N.; Morgan, D.; Selenica, M.L.B. Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. Geroscience, 2022, 44(1), 173-194. doi: 10.1007/s11357-021-00408-z PMID: 34410588
  119. Wischik, C.M.; Novak, M.; Thøgersen, H.C.; Edwards, P.C.; Runswick, M.J.; Jakes, R.; Walker, J.E.; Milstein, C.; Roth, M.; Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1988, 85(12), 4506-4510. doi: 10.1073/pnas.85.12.4506 PMID: 3132715
  120. Horta-Lopez, P.H. Association of α-1-antichymotrypsin expression with the development of conformational changes of tau protein in alzheimer's disease brain. Neuroscience, 2023, 518, 83-100. doi: 10.1016/j.neuroscience.2022.01.002
  121. Flores-Rodríguez, P.; Ontiveros-Torres, M.A.; Cárdenas-Aguayo, M.C.; Luna-Arias, J.P.; Meraz-Ríos, M.A.; Viramontes-Pintos, A.; Harrington, C.R.; Wischik, C.M.; Mena, R.; Florán-Garduño, B.; Luna-Muñoz, J. The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer’s disease. Front. Neurosci., 2015, 9, 33. doi: 10.3389/fnins.2015.00033 PMID: 25717290
  122. Gu, J.; Xu, W.; Jin, N.; Li, L.; Zhou, Y.; Chu, D.; Gong, C.X.; Iqbal, K.; Liu, F. Truncation of Tau selectively facilitates its pathological activities. J. Biol. Chem., 2020, 295(40), 13812-13828. doi: 10.1074/jbc.RA120.012587 PMID: 32737201
  123. Ngian, Z.K.; Tan, Y.Y.; Choo, C.T.; Lin, W.Q.; Leow, C.Y.; Mah, S.J.; Lai, M.K.P.; Chen, C.L.H.; Ong, C.T. Truncated Tau caused by intron retention is enriched in Alzheimer’s disease cortex and exhibits altered biochemical properties. Proc. Natl. Acad. Sci. USA, 2022, 119(37), e2204179119. doi: 10.1073/pnas.2204179119 PMID: 36067305
  124. Lo, C.H. Heterogeneous tau oligomers as molecular targets for alzheimer’s disease and related tauopathies. Biophysica, 2022, 2(4), 440-451. doi: 10.3390/biophysica2040039
  125. Novak, P.; Cehlar, O.; Skrabana, R.; Novak, M. Tau conformation as a target for disease-modifying therapy: The role of truncation. J. Alzheimers Dis., 2018, 64(s1), S535-S546. doi: 10.3233/JAD-179942 PMID: 29865059
  126. Smet-Nocca, C.; Broncel, M.; Wieruszeski, J.M.; Tokarski, C.; Hanoulle, X.; Leroy, A.; Landrieu, I.; Rolando, C.; Lippens, G.; Hackenberger, C.P.R. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. Mol. Biosyst., 2011, 7(5), 1420-1429. doi: 10.1039/c0mb00337a PMID: 21327254
  127. Sato, Y.; Naito, Y.; Grundke-Iqbal, I.; Iqbal, K.; Endo, T. Analysis of N -glycans of pathological tau: Possible occurrence of aberrant processing of tau in Alzheimer’s disease. FEBS Lett., 2001, 496(2-3), 152-160. doi: 10.1016/S0014-5793(01)02421-8 PMID: 11356201
  128. Ledesma, M.D.; Bonay, P.; Colaço, C.; Avila, J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem., 1994, 269(34), 21614-21619. doi: 10.1016/S0021-9258(17)31849-5 PMID: 8063802
  129. Liu, K.; Liu, Y.; Li, L.; Qin, P.; Iqbal, J.; Deng, Y.; Qing, H. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim. Biophys. Acta Mol. Basis Dis., 2016, 1862(2), 192-201. doi: 10.1016/j.bbadis.2015.12.002 PMID: 26655600
  130. Ko, L.; Ko, E.C.; Nacharaju, P.; Liu, W.K.; Chang, E.; Kenessey, A.; Yen, S.H.C. An immunochemical study on tau glycation in paired helical filaments. Brain Res., 1999, 830(2), 301-313. doi: 10.1016/S0006-8993(99)01415-8 PMID: 10366687
  131. Rungratanawanich, W.; Qu, Y.; Wang, X.; Essa, M.M.; Song, B.J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp. Mol. Med., 2021, 53(2), 168-188. doi: 10.1038/s12276-021-00561-7 PMID: 33568752
  132. Lüth, H.J.; Ogunlade, V.; Kuhla, B.; Kientsch-Engel, R.; Stahl, P.; Webster, J.; Arendt, T.; Münch, G. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains. Cereb. Cortex, 2004, 15(2), 211-220. doi: 10.1093/cercor/bhh123 PMID: 15238435
  133. Necula, M.; Kuret, J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem., 2004, 279(48), 49694-49703. doi: 10.1074/jbc.M405527200 PMID: 15364924
  134. Yekta, R.; Sadeghi, L.; Dehghan, G. The role of non-enzymatic glycation on Tau-DNA interactions: Kinetic and mechanistic approaches. Int. J. Biol. Macromol., 2022, 207, 161-168. doi: 10.1016/j.ijbiomac.2022.02.178 PMID: 35257729
  135. Limorenko, G.; Lashuel, H.A. Revisiting the grammar of Tau aggregation and pathology formation: How new insights from brain pathology are shaping how we study and target Tauopathies. Chem. Soc. Rev., 2022, 51(2), 513-565. doi: 10.1039/D1CS00127B PMID: 34889934
  136. Reynolds, M.R.; Berry, R.W.; Binder, L.I. Site-specific nitration and oxidative dityrosine bridging of the τ protein by peroxynitrite: Implications for Alzheimer’s disease. Biochemistry, 2005, 44(5), 1690-1700. doi: 10.1021/bi047982v PMID: 15683253
  137. Maina, M.B. Dityrosine cross-links are present in Alzheimer’s disease-derived tau oligomers and paired helical filaments (PHF) which promotes the stability of the PHF-core tau (297-391) in vitro. bioRxiv, 2022. doi: 10.1101/2022.05.28.493839
  138. Butterfield, D.A.; Reed, T.T.; Perluigi, M.; De Marco, C.; Coccia, R.; Keller, J.N.; Markesbery, W.R.; Sultana, R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res., 2007, 1148, 243-248. doi: 10.1016/j.brainres.2007.02.084 PMID: 17395167
  139. Reynolds, M.R.; Berry, R.W.; Binder, L.I. Site-specific nitration differentially influences τ assembly in vitro. Biochemistry, 2005, 44(42), 13997-14009. doi: 10.1021/bi051028w PMID: 16229489
  140. Zhang, Y.J.; Xu, Y.F.; Liu, Y.H.; Yin, J.; Li, H.L.; Wang, Q.; Wang, J.Z. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J., 2006, 20(9), 1431-1442. doi: 10.1096/fj.05-5223com PMID: 16816118
  141. Weismiller, H.A.; Holub, T.J.; Krzesinski, B.J.; Margittai, M. A thiol-based intramolecular redox switch in four-repeat tau controls fibril assembly and disassembly. J. Biol. Chem., 2021, 297(3), 101021. doi: 10.1016/j.jbc.2021.101021 PMID: 34339733
  142. Prifti, E. Mical modulates Tau toxicity via cysteine oxidation in vivo. Acta Neuropathol. Commun., 2022, 10(1), 1-19. PMID: 34980260
  143. Schiffter, H.A. 5.41 - Pharmaceutical Proteins – Structure, Stability, and Formulation, in Comprehensive Biotechnology, 2nd ed; Academic Press: Burlington, 2011, pp. 521-541.
  144. Watanabe, A.; Takio, K.; Ihara, Y. Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J. Biol. Chem., 1999, 274(11), 7368-7378. doi: 10.1074/jbc.274.11.7368 PMID: 10066801
  145. Ebashi, M.; Toru, S.; Nakamura, A.; Kamei, S.; Yokota, T.; Hirokawa, K.; Uchihara, T. Detection of AD-specific four repeat tau with deamidated asparagine residue 279-specific fraction purified from 4R tau polyclonal antibody. Acta Neuropathol., 2019, 138(1), 163-166. doi: 10.1007/s00401-019-02012-0 PMID: 31006065
  146. Dan, A.; Takahashi, M.; Masuda-Suzukake, M.; Kametani, F.; Nonaka, T.; Kondo, H.; Akiyama, H.; Arai, T.; Mann, D.M.A.; Saito, Y.; Hatsuta, H.; Murayama, S.; Hasegawa, M. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer’s disease brain. Acta Neuropathol. Commun., 2013, 1(1), 54. doi: 10.1186/2051-5960-1-54 PMID: 24252707
  147. Reynolds, M.R.; Reyes, J.F.; Fu, Y.; Bigio, E.H.; Guillozet-Bongaarts, A.L.; Berry, R.W.; Binder, L.I. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J. Neurosci., 2006, 26(42), 10636-10645. doi: 10.1523/JNEUROSCI.2143-06.2006 PMID: 17050703
  148. Lyons, A.J.; Gandhi, N.S.; Mancera, R.L. Molecular dynamics simulation of the phosphorylation-induced conformational changes of a tau peptide fragment. Proteins, 2014, 82(9), 1907-1923. doi: 10.1002/prot.24544 PMID: 24577753
  149. Noble, W.; Hanger, D.P.; Miller, C.C.J.; Lovestone, S. The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol., 2013, 4, 83. doi: 10.3389/fneur.2013.00083 PMID: 23847585
  150. Sibille, N.; Huvent, I.; Fauquant, C.; Verdegem, D.; Amniai, L.; Leroy, A.; Wieruszeski, J.M.; Lippens, G.; Landrieu, I. Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein. Proteins, 2012, 80(2), 454-462. doi: 10.1002/prot.23210 PMID: 22072628
  151. Amniai, L.; Barbier, P.; Sillen, A.; Wieruszeski, J.M.; Peyrot, V.; Lippens, G.; Landrieu, I. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J., 2009, 23(4), 1146-1152. doi: 10.1096/fj.08-121590 PMID: 19074508
  152. Goode, B.L.; Denis, P.E.; Panda, D.; Radeke, M.J.; Miller, H.P.; Wilson, L.; Feinstein, S.C. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol. Biol. Cell, 1997, 8(2), 353-365. doi: 10.1091/mbc.8.2.353 PMID: 9190213
  153. Gandhi, N.S.; Landrieu, I.; Byrne, C.; Kukic, P.; Amniai, L.; Cantrelle, F.X.; Wieruszeski, J.M.; Mancera, R.L.; Jacquot, Y.; Lippens, G. A phosphorylation-induced turn defines the alzheimer’s disease AT8 antibody epitope on the tau protein. Angew. Chem. Int. Ed., 2015, 54(23), 6819-6823. doi: 10.1002/anie.201501898 PMID: 25881502
  154. Rani, L.; Mallajosyula, S.S. Phosphorylation-induced structural reorganization in tau-paired helical filaments. ACS Chem. Neurosci., 2021, 12(9), 1621-1631. doi: 10.1021/acschemneuro.1c00084 PMID: 33877805
  155. Zou, Y.; Guan, L. Unraveling the influence of K280 acetylation on the conformational features of tau core fragment: A molecular dynamics simulation study. Front. Mol. Biosci., 2021, 8, 801577. doi: 10.3389/fmolb.2021.801577 PMID: 34966788
  156. Brotzakis, Z.F.; Lindstedt, P.R.; Taylor, R.J.; Rinauro, D.J.; Gallagher, N.C.T.; Bernardes, G.J.L.; Vendruscolo, M. A structural ensemble of a tau-microtubule complex reveals regulatory tau phosphorylation and acetylation mechanisms. ACS Cent. Sci., 2021, 7(12), 1986-1995. doi: 10.1021/acscentsci.1c00585 PMID: 34963892
  157. Castro, T.G.; Ferreira, T.; Matamá, T.; Munteanu, F.D.; Cavaco-Paulo, A. Acetylation and phosphorylation processes modulate Tau’s binding to microtubules: A molecular dynamics study. Biochim. Biophys. Acta, Gen. Subj., 2023, 1867(2), 130276. doi: 10.1016/j.bbagen.2022.130276 PMID: 36372288
  158. Leonard, C.; Phillips, C.; McCarty, J. Insight into seeded tau fibril growth from Molecular Dynamics simulation of the Alzheimer’s disease protofibril core. Front. Mol. Biosci., 2021, 8, 624302. doi: 10.3389/fmolb.2021.624302 PMID: 33816551
  159. Munari, F.; Mollica, L.; Valente, C.; Parolini, F.; Kachoie, E.A.; Arrigoni, G.; D’Onofrio, M.; Capaldi, S.; Assfalg, M. Structural basis for chaperone-independent ubiquitination of tau protein by its E3 ligase CHIP. Angew. Chem. Int. Ed., 2022, 61(15), e202112374. doi: 10.1002/anie.202112374 PMID: 35107860
  160. Mathew, A.T. N-glycosylation induced changes in tau protein dynamics reveal its role in tau misfolding and aggregation: A microsecond long molecular dynamics study. Proteins, 2022, 91(2), 147-162. doi: 10.26434/chemrxiv-2022-5bs5r
  161. Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement., 2019, 5(1), 272-293. doi: 10.1016/j.trci.2019.05.008 PMID: 31334330
  162. Bush, A.I.; Tanzi, R.E. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics, 2008, 5(3), 421-432. doi: 10.1016/j.nurt.2008.05.001 PMID: 18625454
  163. Travis, J. Roche Alzheimer’s antibody fails to slow cognitive decline in major test; SCIENCEINSIDER, 2022. doi: 10.1126/science.adf8125
  164. Fellner, S.; Bauer, B.; Miller, D.S.; Schaffrik, M.; Fankhänel, M.; Spruß, T.; Bernhardt, G.; Graeff, C.; Färber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest., 2002, 110(9), 1309-1318. doi: 10.1172/JCI0215451 PMID: 12417570
  165. Sengupta, A.; Kabat, J.; Novak, M.; Wu, Q.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys., 1998, 357(2), 299-309. doi: 10.1006/abbi.1998.0813 PMID: 9735171
  166. Ishihara, T.; Hong, M.; Zhang, B.; Nakagawa, Y.; Lee, M.K.; Trojanowski, J.Q.; Lee, V.M.Y. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron, 1999, 24(3), 751-762. doi: 10.1016/S0896-6273(00)81127-7 PMID: 10595524
  167. Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry, 1999, 38(12), 3549-3558. doi: 10.1021/bi981874p PMID: 10090741
  168. Ghoreschi, K.; Laurence, A.; O’Shea, J.J. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat. Immunol., 2009, 10(4), 356-360. doi: 10.1038/ni.1701 PMID: 19295632
  169. Imahori, K.; Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer’s disease. J. Biochem., 1997, 121(2), 179-188. PMID: 9089387
  170. Hernández, F.; Borrell, J.; Guaza, C.; Avila, J.; Lucas, J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem., 2002, 83(6), 1529-1533. doi: 10.1046/j.1471-4159.2002.01269.x PMID: 12472906
  171. Lee, K.Y.; Clark, A.W.; Rosales, J.L.; Chapman, K.; Fung, T.; Johnston, R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res., 1999, 34(1), 21-29. doi: 10.1016/S0168-0102(99)00026-7 PMID: 10413323
  172. Tseng, H.C.; Zhou, Y.; Shen, Y.; Tsai, L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer’s disease brains. FEBS Lett., 2002, 523(1-3), 58-62. doi: 10.1016/S0014-5793(02)02934-4 PMID: 12123804
  173. Noble, W.; Olm, V.; Takata, K.; Casey, E.; Mary, O.; Meyerson, J.; Gaynor, K.; LaFrancois, J.; Wang, L.; Kondo, T.; Davies, P.; Burns, M.; Veeranna; Nixon, R.; Dickson, D.; Matsuoka, Y.; Ahlijanian, M.; Lau, L.F.; Duff, K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron, 2003, 38(4), 555-565. doi: 10.1016/S0896-6273(03)00259-9 PMID: 12765608
  174. Wen, Y.; Planel, E.; Herman, M.; Figueroa, H.Y.; Wang, L.; Liu, L.; Lau, L.F.; Yu, W.H.; Duff, K.E. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci., 2008, 28(10), 2624-2632. doi: 10.1523/JNEUROSCI.5245-07.2008 PMID: 18322105
  175. Drewes, G.; Ebneth, A.; Preuss, U.; Mandelkow, E.M.; Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell, 1997, 89(2), 297-308. doi: 10.1016/S0092-8674(00)80208-1 PMID: 9108484
  176. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102(19), 6990-6995. doi: 10.1073/pnas.0500466102 PMID: 15867159
  177. Hampel, H.; Ewers, M.; Bürger, K.; Annas, P.; Mörtberg, A.; Bogstedt, A.; Frölich, L.; Schröder, J.; Schönknecht, P.; Riepe, M.W.; Kraft, I.; Gasser, T.; Leyhe, T.; Möller, H.J.; Kurz, A.; Basun, H. Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry, 2009, 70(6), 922-931. doi: 10.4088/JCP.08m04606 PMID: 19573486
  178. Gitlin, M. Lithium side effects and toxicity: Prevalence and management strategies. Int. J. Bipolar Disord., 2016, 4(1), 27. doi: 10.1186/s40345-016-0068-y PMID: 27900734
  179. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormö, M.; Nilsson, Y.; Radesäter, A.C.; Jerning, E.; Markgren, P.O.; Borgegård, T.; Nylöf, M.; Giménez-Cassina, A.; Hernández, F.; Lucas, J.J.; Díaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 2003, 278(46), 45937-45945. doi: 10.1074/jbc.M306268200 PMID: 12928438
  180. Nakashima, H.; Ishihara, T.; Suguimoto, P.; Yokota, O.; Oshima, E.; Kugo, A.; Terada, S.; Hamamura, T.; Trojanowski, J.Q.; Lee, V.M.Y.; Kuroda, S. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol., 2005, 110(6), 547-556. doi: 10.1007/s00401-005-1087-4 PMID: 16228182
  181. Engel, T.; Goñi-Oliver, P.; Lucas, J.J.; Avila, J.; Hernández, F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem., 2006, 99(6), 1445-1455. doi: 10.1111/j.1471-4159.2006.04139.x PMID: 17059563
  182. Selenica, M-L.; Jensen, H.S.; Larsen, A.K.; Pedersen, M.L.; Helboe, L.; Leist, M.; Lotharius, J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol., 2007, 152(6), 959-979. doi: 10.1038/sj.bjp.0707471 PMID: 17906685
  183. Naujok, O.; Lentes, J.; Diekmann, U.; Davenport, C.; Lenzen, S. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res. Notes, 2014, 7(1), 273. doi: 10.1186/1756-0500-7-273 PMID: 24779365
  184. Navarro-Retamal, C.; Caballero, J. Molecular modeling of tau proline-directed protein kinase (PDPK) inhibitors. In: Computational Modeling of Drugs Against Alzheimer’s Disease; Roy, K., Ed.; Springer New York: New York, NY, 2018; pp. 305-345. doi: 10.1007/978-1-4939-7404-7_13
  185. Congdon, E.E.; Sigurdsson, E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol., 2018, 14(7), 399-415. doi: 10.1038/s41582-018-0013-z PMID: 29895964
  186. Courade, J.P.; Angers, R.; Mairet-Coello, G.; Pacico, N.; Tyson, K.; Lightwood, D.; Munro, R.; McMillan, D.; Griffin, R.; Baker, T.; Starkie, D.; Nan, R.; Westwood, M.; Mushikiwabo, M.L.; Jung, S.; Odede, G.; Sweeney, B.; Popplewell, A.; Burgess, G.; Downey, P.; Citron, M. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol., 2018, 136(5), 729-745. doi: 10.1007/s00401-018-1911-2 PMID: 30238240
  187. Jadhav, S.; Avila, J.; Schöll, M.; Kovacs, G.G.; Kövari, E.; Skrabana, R.; Evans, L.D.; Kontsekova, E.; Malawska, B.; de Silva, R.; Buee, L.; Zilka, N. A walk through tau therapeutic strategies. Acta Neuropathol. Commun., 2019, 7(1), 22. doi: 10.1186/s40478-019-0664-z PMID: 30767766
  188. Pradeepkiran, J.; Reddy, P. Structure based design and molecular docking studies for phosphorylated tau inhibitors in alzheimer’s disease. Cells, 2019, 8(3), 260. doi: 10.3390/cells8030260 PMID: 30893872
  189. Halliday, M.; Radford, H.; Zents, K.A.M.; Molloy, C.; Moreno, J.A.; Verity, N.C.; Smith, E.; Ortori, C.A.; Barrett, D.A.; Bushell, M.; Mallucci, G.R. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain, 2017, 140(6), 1768-1783. doi: 10.1093/brain/awx074 PMID: 28430857
  190. SantaCruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005, 309(5733), 476-481. doi: 10.1126/science.1113694 PMID: 16020737
  191. Guo, N.; Peng, Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac. J. Clin. Oncol., 2013, 9(1), 6-11. doi: 10.1111/j.1743-7563.2012.01535.x PMID: 22897979
  192. Choi, H.; Kim, H.J.; Yang, J.; Chae, S.; Lee, W.; Chung, S.; Kim, J.; Choi, H.; Song, H.; Lee, C.K.; Jun, J.H.; Lee, Y.J.; Lee, K.; Kim, S.; Sim, H.; Choi, Y.I.; Ryu, K.H.; Park, J.C.; Lee, D.; Han, S.H.; Hwang, D.; Kyung, J.; Mook-Jung, I. Acetylation changes tau interactome to degrade tau in Alzheimer’s disease animal and organoid models. Aging Cell, 2020, 19(1), e13081. doi: 10.1111/acel.13081 PMID: 31763743
  193. Tarjányi, O.; Haerer, J.; Vecsernyés, M.; Berta, G.; Stayer-Harci, A.; Balogh, B.; Farkas, K.; Boldizsár, F.; Szeberényi, J.; Sétáló, G., Jr Prolonged treatment with the proteasome inhibitor MG-132 induces apoptosis in PC12 rat pheochromocytoma cells. Sci. Rep., 2022, 12(1), 5808. doi: 10.1038/s41598-022-09763-z PMID: 35388084
  194. Ohkusu-Tsukada, K.; Ito, D.; Takahashi, K. The role of proteasome inhibitor MG132 in 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int. Arch. Allergy Immunol., 2018, 176(2), 91-100. doi: 10.1159/000488155 PMID: 29669333
  195. Corpas, R.; Griñán-Ferré, C.; Palomera-Ávalos, V.; Porquet, D.; de Frutos, P.G.; Cozzolino, S.M.F.; Rodríguez-Farré, E.; Pallàs, M.; Sanfeliu, C.; Cardoso, B.R. Melatonin induces mechanisms of brain resilience against neurodegeneration. J. Pineal Res., 2018, 65(4), e12515. doi: 10.1111/jpi.12515 PMID: 29907977
  196. Seidler, P.M.; Boyer, D.R.; Rodriguez, J.A.; Sawaya, M.R.; Cascio, D.; Murray, K.; Gonen, T.; Eisenberg, D.S. Structure-based inhibitors of tau aggregation. Nat. Chem., 2018, 10(2), 170-176. doi: 10.1038/nchem.2889 PMID: 29359764
  197. Nixon, R.A. Autophagy in neurodegenerative disease: Friend, foe or turncoat? Trends Neurosci., 2006, 29(9), 528-535. doi: 10.1016/j.tins.2006.07.003 PMID: 16859759
  198. Penke, B.; Bogár, F.; Crul, T.; Sántha, M.; Tóth, M.; Vígh, L. Heat shock proteins and autophagy pathways in neuroprotection: From molecular bases to pharmacological interventions. Int. J. Mol. Sci., 2018, 19(1), 325. doi: 10.3390/ijms19010325 PMID: 29361800
  199. Dickey, C.A.; Dunmore, J.; Lu, B.; Wang, J.W.; Lee, W.C.; Kamal, A.; Burrows, F.; Eckman, C.; Hutton, M.; Petrucelli, L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J., 2006, 20(6), 753-755. doi: 10.1096/fj.05-5343fje PMID: 16464956
  200. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med., 2004, 82(8), 488-499. doi: 10.1007/s00109-004-0549-9 PMID: 15168026
  201. Jilani, K.; Qadri, S.M.; Lang, F. Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell. Physiol. Biochem., 2013, 32(6), 1600-1609. doi: 10.1159/000356596 PMID: 24335345
  202. Ochel, H.J.; Eichhorn, K.; Gademann, G. Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones, 2001, 6(2), 105-112. doi: 10.1379/1466-1268(2001)0062.0.CO;2 PMID: 11599571
  203. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425(6956), 407-410. doi: 10.1038/nature01913 PMID: 14508491
  204. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol., 2004, 11(6), 787-797. doi: 10.1016/j.chembiol.2004.04.008 PMID: 15217612
  205. Hamano, T.; Gendron, T.F.; Causevic, E.; Yen, S.H.; Lin, W.L.; Isidoro, C.; DeTure, M.; Ko, L. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild- type tau expression. Eur. J. Neurosci., 2008, 27(5), 1119-1130. doi: 10.1111/j.1460-9568.2008.06084.x PMID: 18294209
  206. Berger, Z.; Ravikumar, B.; Menzies, F.M.; Oroz, L.G.; Underwood, B.R.; Pangalos, M.N.; Schmitt, I.; Wullner, U.; Evert, B.O.; O’Kane, C.J.; Rubinsztein, D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet., 2006, 15(3), 433-442. doi: 10.1093/hmg/ddi458 PMID: 16368705
  207. Morita, T.; Sobue, K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem., 2009, 284(40), 27734-27745. doi: 10.1074/jbc.M109.008177 PMID: 19648118
  208. Bresinsky, M.; Strasser, J.M.; Vallaster, B.; Liu, P.; McCue, W.M.; Fuller, J.; Hubmann, A.; Singh, G.; Nelson, K.M.; Cuellar, M.E.; Wilmot, C.M.; Finzel, B.C.; Ashe, K.H.; Walters, M.A.; Pockes, S. Structure-based design and biological evaluation of novel caspase-2 inhibitors based on the peptide AcVDVAD-CHO and the caspase-2-mediated tau cleavage sequence YKPVD314. ACS Pharmacol. Transl. Sci., 2022, 5(1), 20-40. doi: 10.1021/acsptsci.1c00251 PMID: 35059567
  209. Yuzwa, S.A.; Macauley, M.S.; Heinonen, J.E.; Shan, X.; Dennis, R.J.; He, Y.; Whitworth, G.E.; Stubbs, K.A.; McEachern, E.J.; Davies, G.J.; Vocadlo, D.J. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol., 2008, 4(8), 483-490. doi: 10.1038/nchembio.96 PMID: 18587388
  210. Yu, Y.; Zhang, L.; Li, X.; Run, X.; Liang, Z.; Li, Y.; Liu, Y.; Lee, M.H.; Grundke-Iqbal, I.; Iqbal, K.; Vocadlo, D.J.; Liu, F.; Gong, C.X. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One, 2012, 7(4), e35277. doi: 10.1371/journal.pone.0035277 PMID: 22536363
  211. Selnick, H.G.; Hess, J.F.; Tang, C.; Liu, K.; Schachter, J.B.; Ballard, J.E.; Marcus, J.; Klein, D.J.; Wang, X.; Pearson, M.; Savage, M.J.; Kaul, R.; Li, T.S.; Vocadlo, D.J.; Zhou, Y.; Zhu, Y.; Mu, C.; Wang, Y.; Wei, Z.; Bai, C.; Duffy, J.L.; McEachern, E.J. Discovery of MK-8719, a potent o-glcnacase inhibitor as a potential treatment for tauopathies. J. Med. Chem., 2019, 62(22), 10062-10097. doi: 10.1021/acs.jmedchem.9b01090 PMID: 31487175
  212. ASN90 2022. Available from: https://www.alzforum.org/therapeutics/asn90
  213. Yuzwa, S.A.; Shan, X.; Macauley, M.S.; Clark, T.; Skorobogatko, Y.; Vosseller, K.; Vocadlo, D.J. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol., 2012, 8(4), 393-399. doi: 10.1038/nchembio.797 PMID: 22366723
  214. Younes, M.; Aggett, P.; Aguilar, F.; Crebelli, R.; Dusemund, B.; Filipič, M.; Frutos, M.J.; Galtier, P.; Gott, D.; Gundert-Remy, U.; Lambré, C.; Leblanc, J.C.; Lillegaard, I.T.; Moldeus, P.; Mortensen, A.; Oskarsson, A.; Stankovic, I.; Waalkens-Berendsen, I.; Woutersen, R.A.; Andrade, R.J.; Fortes, C.; Mosesso, P.; Restani, P.; Arcella, D.; Pizzo, F.; Smeraldi, C.; Wright, M. Scientific opinion on the safety of green tea catechins. EFSA J., 2018, 16(4), e05239. PMID: 32625874
  215. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? Int. J. Mol. Sci., 2011, 12(9), 5592-5603. doi: 10.3390/ijms12095592 PMID: 22016611
  216. Sonawane, S.K.; Chinnathambi, S. Epigallocatechin-3-gallate modulates tau post-translational modifications and cytoskeletal network. Oncotarget, 2021, 12(11), 1083-1099. doi: 10.18632/oncotarget.27963 PMID: 34084282
  217. Seidler, P.M.; Murray, K.A.; Boyer, D.R.; Ge, P.; Sawaya, M.R.; Hu, C.J.; Cheng, X.; Abskharon, R.; Pan, H.; DeTure, M.A.; Williams, C.K.; Dickson, D.W.; Vinters, H.V.; Eisenberg, D.S. Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro. Nat. Commun., 2022, 13(1), 5451. doi: 10.1038/s41467-022-32951-4 PMID: 36114178
  218. Inuzuka, H.; Liu, J.; Wei, W.; Rezaeian, A.H. PROTAC technology for the treatment of Alzheimer’s disease: Advances and perspectives. Acta Materia Medica, 2022, 1(1), 24-41. doi: 10.15212/AMM-2021-0001 PMID: 35237768
  219. Li, C.; Götz, J. Tau-based therapies in neurodegeneration: Opportunities and challenges. Nat. Rev. Drug Discov., 2017, 16(12), 863-883. doi: 10.1038/nrd.2017.155 PMID: 28983098

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bentham Science Publishers, 2024